

## COVID-19 Supply Chain System Purchasing Consortia Status as of 28 April 2020

## **Diagnostics**

The diagnostics consortium has secured commitments from suppliers for a stockpile of tests and related consumables for low and middle income countries over the next 16 weeks. This includes up to about 10 million automated tests for SARS-CoV-2, and 20 million manual tests, for a total of approximately 30 million tests that will be available during this first period. We estimate that the available manual tests will approach the capacity of countries to consume them. WHO has focused on securing tests that are provided as complete kits and with contamination controls, to simplify ordering and reduce the risk of service interruptions.

We will continue to exercise all possible efforts to grow the stockpile of automated tests.

Committed diagnostic tests by product group

Product				
group	Next 1-4 weeks	Next 5-8 weeks	Next 9-12 weeks	Next 13-16 weeks
Automated	835,000 (up to	1,528,000 (up to	1,983,000 (up to	2,530,000 (up to
Tests <sup>1</sup>	950,000)	1,780,000)	2,805,000)	3,765,000)
Manual Tests	5,200,000	5,200,000	5,200,000	5,200,000
Swabs + Media <sup>2</sup>	6,241,000 (up to 6,393,000)	6,728,000 (up to 6,980,000)	7,183,000 (up to 8,005,000)	7,730,000 (up to 8,965,000)

In partnership with FIND, WHO continues to evaluate the pipeline of antigen tests; though none have yet demonstrated acceptable performance, in the future they will be added if products with acceptable performance are identified.

## **Clinical Management**

The Clinical Operations pillar has progressed on multiple levels. Global demand was forecasted for priority items via v2 of ESFT and the assessment of country absorptive capacity was initiated via the Inventory Tool and private sector mapping. Allocation principles were reviewed with key partners and have been agreed upon. WHO has also moved forward with sourcing as it has identified available supply for all of the priority items, such as concentrators, PSA plants, liquid oxygen and accessories and consumables linked to oxygen therapy. In parallel, WHO has also started to identify the supply pipeline for other items (e.g., ventilators).

<sup>&</sup>lt;sup>2</sup> Volumes of sample collection materials will depend in part on how many tests are procured.



<sup>&</sup>lt;sup>1</sup> Manufacturers have committed the minimum volumes, and have agreed to make their best efforts to provide the higher amount indicated. Some automated test manufacturers limited which regions or which LMIC countries can receive the supplies sold through the stockpile. Continuing negotiations seek to expand the stocks and to increase availability for all regions.



As many of the items on the supply list have already been validated, WHO has been able to start issuing purchase orders.

The procurement strategy of the consortium, including roles and responsibilities, is being refined. However, the visibility on current procurement activities is currently still limited, not only regarding procurement within consortium but also outside (e.g., countries' current supply capacity, existing infrastructure, activities of other agencies). To resolve this, procurement roles and responsibilities need to be detailed quickly and supply data needs to be shared. Also, other procuring (UN) agencies are to be engaged and an inclusion in consortium to be discussed (e.g., UNFPA, UNDP, UNOPS). While a weekly meeting rhythm for the consortium was established, operational working groups (data consolidation, allocation, and other as needed) must be set up within the consortium, with each partner nominating representatives.

Committed clinical supplies products by product group

ommitted clinical supplies products by product group							
		Next	N	N 10 10	N . 42		
Product	Tatal	1-4	Next	Next 9-12	Next 13-		
	Total	weeks	5-8 weeks	weeks	24 weeks		
Monitoring devices - Medical Equipment							
Pulse oximeter	130,550	8,450	54,200	41,700	26,200		
Patient monitor	115,710	9,640	41,650	33,220	31,200		
Oxygen plant, pressure swing absorption (PSA)	1,295	96	228	325	646		
Concentrators, with accessories	275,855	27,135	70,840	90,140	87,740		
Oxygen therapy - Access/ consumables linked to equipment							
Bubble humidifier	12,000	2,000	5,000	5,000			
Connector, biconical, symmetric, ext. diam. 7-11 mm, autoclavable	28,000	4,000	12,000	12,000			
Flowmeter, Thorpe tube, for oxygen 0-15 L/min	250	50	100	100			
Oxygen delivery devices - Consuma	bles (single	use devices	s)				
Nasal cannula (adult & paed.)	67,000	13,000	27,000	27,000			
Mask, oxygen, w/ connection tube, reservoir bag, & valve	26,000	6,000	10,000	10,000			
Venturi mask, with % O2 lock & tubing	1,550	350	600	600			

<sup>\*</sup> NOTE: Not all supply validated





## **Infection Prevention and Control**

For the PPE pillar, the demand estimations indicated that demand far outpaces currently available capacity. Multi-channel sourcing will be critical to maximize the response to it. Currently, two key sources of supply were identified and agreed upon, which are UNICEF and WHO. A joint tender initiated by UNICEF & Procurement Reference Group was already established to coordinate the PPE pipelines and there are ongoing talks to transform this into the PPE Consortium.

**Committed IPC products by product group** 

Product	oduct Next Next					
group	Product	Total	1-4 weeks	5-8 weeks		
Masks	Surgical mask, non sterile	202,183,000 (plus 339,500,000 planned)	31,298,000 (plus 15,000,000 planned)	170,886 (plus 324,500 planned)		
	Particulate respirator (N95)	50,727,000	492,000	50,207,000		
Body protection	Protective gown	445,000 (plus 13,950,000 planned)	353,000 (plus 300,000 planned)	92,000 (plus 13,650,000 planned)		
Eye protection	Protective goggles	3,157 (plus 3,000,000 planned)	985,000	2,172,000 (plus 3,000,000 planned)		
	Face shield	(17,000 planned)	(1,000 planned)	(16,000,000 planned)		
Gloves	Gloves	77,574,000 (plus 10,000,000 planned)	1,152,000	76,422,000 (plus 10,000,000 planned)		
Disinfectant	Alcohol-based hand rub	66,000	55,000	9,000		

